Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Cell surface marker for detecting circulating tumor cells of breast cancer patient and application

A cell surface and tumor cell technology, applied in the field of cell surface markers for detection of CTCs in breast cancer patients, can solve the problems of inapplicability to tumors, lack of CTCs, and inability to capture, and achieve efficient capture of breast cancer CTCs, efficient capture, and accurate information. and strong support

Pending Publication Date: 2022-01-11
WEST CHINA HOSPITAL SICHUAN UNIV
View PDF6 Cites 0 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

This fixed antibody combination obviously cannot be applied to all types of tumors, especially CTCs that lack the above surface markers cannot be captured, resulting in missed detection

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Cell surface marker for detecting circulating tumor cells of breast cancer patient and application
  • Cell surface marker for detecting circulating tumor cells of breast cancer patient and application
  • Cell surface marker for detecting circulating tumor cells of breast cancer patient and application

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0047] Prepare or purchase TSPAN1, FAIM2, KCNJ4, GABRD, PDK1L2, OR1OK1, UPK1B and OR51M1 antibodies, respectively coat the chip with these antibodies, and test the ability of each antibody to enrich and screen breast cancer cells (methods such as image 3 shown, excluding blood samples). In this example, classic breast cancer cells SKBR3 and MCF-7 were selected as experimental cells. After coating the chip, the cultured SKBR3 and MCF-7 cells were counted, 1000 cells in each group, flowed through the chip at a certain speed, and the cells captured by the chip were collected with the collection solution and counted. The capture ability of different antibodies on SKBR3 and MCF-7 breast cancer cells was counted. The result is as Figure 4 , the y-axis represents the capture efficiency, that is, the percentage of captured cells enriched by a single antibody. The x-axis represents newly developed breast cancer CTCs specifically expressing surface marker antibodies.

[0048] It c...

Embodiment 2

[0050] Use the screened surface marker antibody combined with EpCam to test the ability of superimposed antibody enrichment to capture breast cancer tumor cells (method such as image 3 shown, excluding blood samples). The result is as Figure 5 As shown, the y-axis represents the capture efficiency, that is, the percentage of antibody-enriched captured cells. The x-axis represents EpCam and its combination with other newly developed surface marker antibodies. The mass ratio of EpCam and corresponding antibody is 1:1.

[0051] The classic breast cancer cells SKBR3 and MCF-7 were selected as experimental cells. After coating the chip, the cultured SKBR3 and MCF-7 cells were counted, 1000 cells in each group, flowed through the chip at a certain speed, and the cells captured by the chip were collected with the collection solution and counted. The capture ability of different antibodies on SKBR3 and MCF-7 breast cancer cells was counted. It can be seen from the figure that t...

Embodiment 3

[0053] Use the screened surface marker antibody combined with HER2 to test the ability of superimposed antibody enrichment to capture breast cancer tumor cells (method such as image 3 shown, excluding blood samples). The result is as Image 6 As shown, the y-axis represents the capture efficiency, that is, the percentage of antibody-enriched captured cells. The x-axis represents HER2 and combinations with other newly developed surface marker antibodies. The mass ratio of HER2 and corresponding antibody is 1:1.

[0054] The classic breast cancer cells SKBR3 and MCF-7 were selected as experimental cells. After coating the chip, the cultured SKBR3 and MCF-7 cells were counted, 1000 cells in each group, flowed through the chip at a certain speed, and the cells captured by the chip were collected with the collection solution and counted. The capture ability of different antibodies on SKBR3 and MCF-7 breast cancer cells was counted. It can be seen from the figure that the comb...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The invention discloses a cell surface marker for detecting circulating tumor cells of a breast cancer patient and application of the cell surface marker, the cell surface marker comprising TSPAN1, FAIM2, KCNJ4, GABRD, PDK1L2, OR1OK1, UPK1B and OR51M1, wherein immunocapture is performed on breast cancer CTC by adopting an antibody corresponding to the cell surface marker. According to the present invention, with the obtained breast cancer patient circulating tumor cell surface marker, the optimal antibody combination for immune enrichment screening is obtained, such that the breast cancer CTC enrichment capture efficiency is improved, the CTC capture specificity and the CTC capture sensitivity are effectively improved, and the efficient breast cancer CTC capture effect is provided. Therefore, the problems that the existing breast cancer CTC enrichment markers are insufficient in variety, low in detection rate and low in purity are solved.

Description

technical field [0001] The invention relates to the technical field of tumor cell detection, in particular to cell surface markers and applications for detecting CTCs of breast cancer patients. Background technique [0002] Circulating tumor cells (CTCs) refer to tumor cells detached from tumor tissues and released into the blood circulation system, which can truly characterize tumor burden and characteristics, dynamically reflect tumor genomics information and changes in gene expression profiles, and are related to patient tumors. Distant metastasis is closely related, which is of great significance for the diagnosis of malignant tumors and the judgment of clinical staging. At present, the research on CTC in early tumor screening, dynamic monitoring and immunotherapy selection has achieved remarkable results, and CTC detection has become one of the most promising non-invasive tumor diagnosis and treatment methods. And its field of liquid biopsy was rated as one of the top ...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
IPC IPC(8): G01N15/14G01N33/50
CPCG01N15/14G01N33/5005G01N2015/1486
Inventor 何秀静
Owner WEST CHINA HOSPITAL SICHUAN UNIV
Features
  • Generate Ideas
  • Intellectual Property
  • Life Sciences
  • Materials
  • Tech Scout
Why Patsnap Eureka
  • Unparalleled Data Quality
  • Higher Quality Content
  • 60% Fewer Hallucinations
Social media
Patsnap Eureka Blog
Learn More

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2025 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com